Cold agglutinin disease
Drug research and approvals for cold agglutinin disease: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 16, 2026, 4 studies of cold agglutinin disease are recruiting on ClinicalTrials.gov, Health Canada has authorized 5 drug trials for it since 2013, FDA has 2 approved and 0 open orphan designations naming it, and the EU has 1 authorised medicine for it.
- Recruiting worldwide: 4
- Trials authorized in Canada: 5
- FDA orphan approvals: 2
- EU medicines: 1
Recruiting Now
Newest start dates first, of 4 recruiting on ClinicalTrials.gov ↗- OM336 in Autoimmune CytopeniasNCT07083960 · Phase 1 · Lakefront Biotherapeutics West LLC · starts Aug 1, 2025
- Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study in Healthy Male and Female Subjects and Safety,…NCT05318534 · Phase 1 · Gliknik Inc. · starts Apr 8, 2022
- Prospective Evaluation of Diagnosis and Treatment of Patients With Autoimmune Cytopenias Including Autoimmune Hemolytic…NCT05931718 · Not reported · Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico · starts Jun 1, 2019
- National Longitudinal Cohort of Hematological Diseases- Autoimmune Hemolytic AnemiaNCT07019038 · Not reported · Institute of Hematology & Blood Diseases Hospital, China · starts Jan 1, 2001
Trials Authorized in Canada
Newest first; search them all in Canada trials| May 17, 2022 | A phase 3, randomized, double-blind, placebo-controlled multicenter study to evaluate the efficacy and safety of pegcetacoplan in patients with cold agglutinin…PEGCETACOPLAN (APL-2) | Swedish Orphan Biovitrum | Closed |
| Sep 15, 2020 | An open label, long term, safety and tolerability study of patients with cold agglutinin disease previously treated with bivv020BIVV020 | SANOFI-AVENTIS CANADA INC | Pending |
| Feb 11, 2020 | A multicenter, phase 1b, open label, nonrandomized, single dose study evaluating the safety, tolerability and activity of bivv020 in adults with cold…BIVV020 | SANOFI-AVENTIS CANADA INC | Ongoing |
| Dec 15, 2017 | A phase 3, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of bivv009 in patients with primary cold agglutinin disease…BIVV009 | Sanofi | Ongoing |
| Dec 15, 2017 | A pivotal, open-label, multicenter study to assess the efficacy and safety of bivv009 in patients with primary cold agglutinin disease who have a recent…BIVV009 | Sanofi | Closed |
FDA Orphan Designations
Approved first, then open designations, newest first| Jan 25, 2023 | Enjaymotreatment of hemolysis in adults with cold agglutinin disease (CAD) | Recordati Rare Diseases Inc. | Approved |
| Feb 4, 2022 | EnjaymoTo decrease the need for red blood cell (RBC) transfusion due to hemolysis in adults with cold agglutinin disease (CAD) | Recordati Rare Diseases Inc. | Approved |
Medicines Authorised in the EU
Newest first| Authorised | Medicine | Holder | EPAR |
|---|---|---|---|
| Nov 15, 2022 | Enjaymosutimlimab · orphan | Recordati Rare Diseases | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA